

PO-279: What is the optimal MAB use ratio per 100.000 inhabitants in centers with Headache Unit or monografic headache clinic? Estimation from the Galca-Only and Frema-Only consortium

Victor Obach¹, Alberto Andres Lopez², Alberto Lozano³, Alexandra Figueroa⁴, Almudena Layos⁵, Ana Echavarría Iñiguez⁶, Antonio Sanchez Soblechero³, Beartiz Alavarez-Mariño⁷, Fernando Iglesias⁸, Laura Rubio⁹, Manuel Peinado⁹, Maria Recio¹⁰, Raquel Portillo¹⁰, Sendo Gil Luque⁶, Yesica Gonzalez-Osorio¹¹, Sonssoles Aranzeta¹², Elisa Cuadrado¹³, Neus s Fabregat¹⁴, Teresa Marco¹⁵, Santiago Fernandez Fernandez¹⁴, Ana Rizo¹⁴, Nuria Pola¹⁵, Nagore Urduri¹⁶, Ane Minguez¹⁷, Marta Ruibal¹⁷, Alba Bravo¹⁸, Rocio Alvarez¹⁹, Nuria Riesco¹⁹, Fernando Velasco²⁰, Aintzine Ruizanchez²¹, Iزارo Kortazar²², Amaya Echeberria²², Maria Martin Bujante²³, Juna Carlos Garcia-Monco²⁴, David Garcia-Azorin²¹
¹Barcelona, Barcelona, Spain. ²Hospital General de Albacete, Albacete, Spain. ³Hospital General Gregorio Marañon, Madrid, Spain. ⁴Hospital Infanta Elena, Madrid, Spain. ⁵Hospital Albacete, Albacete, Spain. ⁶Hospital Universitario de de Burgos, Burgos, Spain. ⁷Hospital Rey Juan Carlos, Madrid, Spain. ⁸Hospital General de Villalba, Madrid, Spain. ⁹Hospital General de Castellon, Castellon, Spain. ¹⁰Hospital Reina Sofia, Cordoba, Spain. ¹¹Hospital de Valladolid, Valladolid, Spain. ¹²Hospital Tauli, Sabadell, Spain. ¹³Hospital del Mar, Barcelona, Spain. ¹⁴Hospital Clinic, Barcelona, Spain. ¹⁵Hospital Clinic, Barcelona, Spain. ¹⁶Hospital Urduriz, Bilbao, Spain. ¹⁷Hospital Donosti, San Sebastian, Spain. ¹⁸Hospital Reina Sofia, Tudela, Spain. ¹⁹Hospital de Asturias, Oviedo, Spain. ²⁰Hospital de Cruces, Bilbao, Spain. ²¹Hospital Galdakoa, Bilbao, Spain. ²²Hospital Txagorritzu, Alava, Spain. ²³Hospital Navarra, Pamplona, Spain. ²⁴Hospital de Basurto, Bilbao, Spain

OBJETIVE

Anti-calcitonin gene-related peptide (CGRP) monoclonal antibodies (mAB) for migraine prophylaxis have been approved in 2019 in Spain and therefore expertise and logistics in its use have been established. We analyze the experience in 20 centers participating in 2 large multicentric registries

METHODS

Pharmaco-therapeutic Commissions of 20 centers with Headache Units or monografic headache consults, approved Galcanezumab (GalcaOnly) or Fremanezumab (FremaOnly) use in 2020 as the first line mAB option treatment of high frequency (>7 attacks per month, refractory to three or more oral migraine preventive treatments) or chronic migraineurs refractory to at least two oral migraine preventives and onabotulinumtoxinA), according to the Spanish health regulation. In Spain, the healthcare system is public and universally covers all inhabitants, with the mABs being free of charge when the patients met the aforementioned requirements.

Herein, consecutive patients treated with mABs were interviewed for demographics and monthly headache days (MHDs) and were included in this two registries, GalcaOnly Consortium and FremaOnly Consortium. The novo patients with mAB initiation from January to March 2023 were recorded in 20 centers covering 6.361.500 reference population. The ratio of monthly mAB initiation per 100.000 inhabitants was calculated from each center.

RESULTS

A total of 546 de novo mABs were prescribed in 3 month-period in the 20 centers resulting a ratio of 2.86 mAB per month per 100-000 inhabitant. Three centers have a ratio of more than 5 prescription per month per 100.000 inhabitants.

CONCLUSION

The optimal MABs prescription ratio per 100.000 inhabitants is unknown and depends on many variables but 2.8 / months/100000 inhabitants targeted is feasible in many centers